Advances in Oncologic Therapies During Pregnancy: Balancing Maternal Cure With Fetal Safety in Reproductive Cancers
Technology in Cancer Research & Treatment · 2026
DOI: 10.1177/15330338261494984 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Valentina Schiavoni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Section of Biochemistry, Università Politecnica Delle Marche, Ancona, Italy. Hauptthemen laut MEDLINE: Pregnancy Complications, Neoplastic, Genital Neoplasms, Female. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Gynecologic cancer during pregnancy requires treatment decisions that preserve maternal oncologic efficacy while minimizing fetal harm. This focused narrative review critically evaluates systemic therapy for cervical, ovarian, and other selected gynecologic malignancies during pregnancy, with surgery, radiotherapy, obstetric outcomes, and emerging technologies discussed only when they directly inform systemic-treatment decisions. Evidence is interpreted using a transparent four-category framework based on study design, consistency, directness, and applicability to pregnancy. The most consistent evidence supports avoiding cytotoxic chemotherapy during organogenesis and permits selected standard-dose regimens after the first trimester when maternal benefit justifies treatment. Anthracycline-, taxane-, and platinum-based regimens are supported predominantly by international cohorts, registries, and case series rather than randomized trials. Evidence for targeted agents and immune checkpoint inhibitors remains sparse, indirect, and vulnerable to reporting bias; therefore, these treatments should generally be deferred during pregnancy unless an individualized multidisciplinary assessment identifies a compelling maternal indication and no effective alternative. Nanomedicine remains preclinical and is summarized solely as a future research direction. This evidence-calibrated approach emphasizes indication-specific treatment, avoidance of iatrogenic prematurity, and prospective maternal and offspring follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Section of Biochemistry, Università Politecnica Delle Marche, Ancona, Italy.
- Department of Clinical Sciences, Clinic of Obstetrics and Gynaecology, Università Politecnica Delle Marche, Ancona, Italy.
- Department of Experimental and Clinical Medicine, Università Politecnica Delle Marche, Ancona, Italy.
- Department for the Promotion of Human Science and Quality of Life, San Raffaele Roma University, Rome, Italy.
- IRCCS San Raffaele Roma, Cassino, Italy.
- Ospedali Riuniti, Ancona, Italy.
ORCID-Profile: Monia Cecati
Zitieren
APA
Schiavoni, V., Giannubilo, S. R., Grelloni, C., Vignini, A., Marzioni, D., Rotondo, R., Cecati, M., Campagna, R., Sartini, G., & Ciavattini, A. (2026). Advances in Oncologic Therapies During Pregnancy: Balancing Maternal Cure With Fetal Safety in Reproductive Cancers. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261494984
Vancouver
Schiavoni V, Giannubilo SR, Grelloni C, Vignini A, Marzioni D, Rotondo R, et al. Advances in Oncologic Therapies During Pregnancy: Balancing Maternal Cure With Fetal Safety in Reproductive Cancers. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261494984
BibTeX
@article{Schiavoni2026,
author = {Schiavoni, Valentina and Giannubilo, Stefano Raffaele and Grelloni, Camilla and Vignini, Arianna and Marzioni, Daniela and Rotondo, Rossella and Cecati, Monia and Campagna, Roberto and Sartini, Gianmarco and Ciavattini, Andrea},
title = {Advances in Oncologic Therapies During Pregnancy: Balancing Maternal Cure With Fetal Safety in Reproductive Cancers},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
doi = {10.1177/15330338261494984}
}
EUVIMED